Growth Metrics

Merck (MRK) Amortizatization of Intangibles (2020 - 2026)

Merck (MRK) reported Amortizatization of Intangibles of $931.0 million for Q1 2026, up 55.95% year-over-year from $597.0 million in Q1 2025, and down 4.32% on a QoQ basis from $973.0 million in Q4 2025.

Merck (MRK) has 7 years of Amortizatization of Intangibles data on file, last reported at $931.0 million in Q1 2026.

  • Quarterly Amortizatization of Intangibles rose 55.95% year-over-year to $931.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $3.1 billion (up 24.18% YoY) and the FY2025 annual result came in at $2.8 billion, up 16.62% from the prior year.
  • Amortizatization of Intangibles fell to $931.0 million in Q1 2026 per MRK's latest filing, from $973.0 million in the prior quarter.
  • Across five years, Amortizatization of Intangibles topped out at $973.0 million in Q4 2025 and bottomed at $460.0 million in Q3 2022.
  • The 5-year median for Amortizatization of Intangibles is $597.0 million (2025), against an average of $602.8 million.
  • The widest annual swing landed in 2023, when Amortizatization of Intangibles slipped 22.32%; it then jumped 55.95% in 2026.
  • Tracing MRK's Amortizatization of Intangibles over 5 years: stood at $462.0 million in 2022, then changed by 0.0% to $462.0 million in 2023, then surged by 46.1% to $675.0 million in 2024, then soared by 44.15% to $973.0 million in 2025, then fell by 4.32% to $931.0 million in 2026.
  • Per Business Quant, the three latest MRK Amortizatization of Intangibles figures stand at $931.0 million (Q1 2026), $973.0 million (Q4 2025), and $623.0 million (Q3 2025).

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Amortizatization of Intangibles (Qtr)
1 Novartis Ag 107,124,802.25 Bn 107,124,802.25 Bn - -
2 Eli Lilly 969.00 Bn 963.72 Bn 16.22 Bn -
3 Johnson & Johnson 539.46 Bn 517.41 Bn 15.96 Bn -
4 AbbVie 376.92 Bn 367.57 Bn 10.78 Bn 1.70 Bn
5 Merck 285.00 Bn 279.35 Bn 12.09 Bn 931.00 Mn
6 Amgen 177.58 Bn 165.55 Bn 5.87 Bn -
7 Gilead Sciences 163.22 Bn 155.50 Bn 5.52 Bn 596.00 Mn
8 Pfizer 145.86 Bn 133.09 Bn -1.21 Bn -
9 Bristol Myers Squibb 111.90 Bn 101.44 Bn 8.07 Bn -
10 Gsk 88.34 Bn 83.66 Bn - -

Historic Data

Download Data 🔒
DateValue
Mar 31, 2026 931.00 Mn
Mar 31, 2026 931.00 Mn
Dec 31, 2025 973.00 Mn
Dec 31, 2025 973.00 Mn
Sep 30, 2025 623.00 Mn
Sep 30, 2025 623.00 Mn
Jun 30, 2025 601.00 Mn
Jun 30, 2025 601.00 Mn
Mar 31, 2025 597.00 Mn
Mar 31, 2025 597.00 Mn
Dec 31, 2024 675.00 Mn
Dec 31, 2024 675.00 Mn
Sep 30, 2024 633.00 Mn
Sep 30, 2024 633.00 Mn
Jun 30, 2024 614.00 Mn
Jun 30, 2024 614.00 Mn
Mar 31, 2024 473.00 Mn
Mar 31, 2024 473.00 Mn
Dec 31, 2023 462.00 Mn
Dec 31, 2023 462.00 Mn
Sep 30, 2023 562.00 Mn
Sep 30, 2023 562.00 Mn
Jun 30, 2023 477.00 Mn
Jun 30, 2023 477.00 Mn
Mar 31, 2023 543.00 Mn
Mar 31, 2023 543.00 Mn
Dec 31, 2022 462.00 Mn
Dec 31, 2022 462.00 Mn
Sep 30, 2022 460.00 Mn
Sep 30, 2022 460.00 Mn
Jun 30, 2022 463.00 Mn
Jun 30, 2022 463.00 Mn
Mar 31, 2022 699.00 Mn
Mar 31, 2022 699.00 Mn
Dec 31, 2021 405.00 Mn
Dec 31, 2021 405.00 Mn
Sep 30, 2021 360.00 Mn
Sep 30, 2021 360.00 Mn
Jun 30, 2021 357.00 Mn
Jun 30, 2021 357.00 Mn
Mar 31, 2021 514.00 Mn
Mar 31, 2021 514.00 Mn
Dec 31, 2020 424.00 Mn
Dec 31, 2020 424.00 Mn
Sep 30, 2020 406.00 Mn
Sep 30, 2020 406.00 Mn
Jun 30, 2020 599.00 Mn
Jun 30, 2020 599.00 Mn
Mar 31, 2020 410.00 Mn
Mar 31, 2020 410.00 Mn